Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL27272413 | 0.92 | GABRA1 (0.52) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL31667256 | 0.87 | BRD4 (0.40) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL28302984 | 0.84 | ALDH1A1 (0.40) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL28875645 | 0.80 | ALDH1A1 (0.49) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL27667384 | 0.79 | BRD4 (0.50) | BRD4ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL2280624 | 0.79 | ALDH1A1 (0.46) | BRD4ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL31186124 | 0.78 | ALDH1A1 (0.58) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL26618992 | 0.78 | BRD4 (0.50) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL18256948 | 0.77 | ALDH1A1 (0.60) | BRD4ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL12890135 | 0.77 | ALDH1A1 (0.47) | BRD4ALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2023220238-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| CN-113166100-A | Immunomodulatory compounds | 达纳-法伯癌症研究所有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3814330-A1 | IMMUNOMODULATORY COMPOUNDS | Dana-Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184434-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2016-11-24 | — | — | WO | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | BRD4 4102/4885ALDH1A1 1635/4885KDM4E 3968/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | BRD4 3330/4885ALDH1A1 1929/4885KDM4E 4855/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | BRD4 53/4885ALDH1A1 3735/4885KDM4E 444/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | BRD4 223/4885ALDH1A1 4827/4885KDM4E 391/4885 |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | CRBN, CD47, CD58 | BRD4 382/4885ALDH1A1 3939/4885KDM4E 2386/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | BRD4 223/4885ALDH1A1 4827/4885KDM4E 391/4885 |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | BRD4 1310/4885ALDH1A1 3998/4885KDM4E 3309/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | BRD4 382/4885ALDH1A1 3939/4885KDM4E 2386/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | BRD4 3330/4885ALDH1A1 1929/4885KDM4E 4855/4885 |
| US-20090306103-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | MKI67, FLT4, VEGFA | BRD4 549/4885ALDH1A1 1992/4885KDM4E 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.